[Nphe¹]-Nociceptin (1-13)-NH₂, a nociceptin receptor antagonist, reverses nociceptin-induced spatial memory impairments in the Morris water maze task in rats

¹J.P. Redrobe, ²G. Calo, ²R. Guerrini, ²D. Regoli & ^{*,1}R. Quirion

¹Douglas Hospital Research Centre, Department of Psychiatry, McGill University, 6875 Blvd LaSalle, Verdun, QC, Canada, H4H 1R3 and ²Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Via Fossato di Mortara, 44100 Ferrara, Italy

1 The present study was undertaken to investigate the effects of the novel nociceptin receptor antagonist, [Nphe¹]-Nociceptin (1-13)-NH₂ (bilateral intrahippocampal injection, 50 nmole rat⁻¹) on purported nociceptin-induced (bilateral intrahippocampal injection, 5 nmole rat⁻¹) deficits in spatial learning in the rat Morris water maze task. In addition, experiments were performed in an 'open field' to investigate possible peptide-induced changes in exploratory behaviour.

2 Nociceptin significantly impaired the ability of the animal to locate the hidden platform throughout training ($P < 0.001$ versus control group).

3 Pretreatment with [Nphe¹]-Nociceptin (1-13)-NH₂ significantly blocked nociceptin-induced impairment of spatial learning ($P < 0.001$ versus nociceptin group).

4 A probe trial revealed that vehicle-treated animals spent more time in the quadrant that had previously contained the hidden platform, whereas nociceptin-treated animals did not spend more time in any one quadrant.

5 Learning impairments were not attributable to non-specific deficits in motor performance or change in exploratory behaviour.

6 Taken together, our results reveal that [Nphe¹]-Nociceptin (1-13)-NH₂ represents an effective and useful *in vivo* antagonist at the nociceptin receptors involved in learning and memory.

British Journal of Pharmacology (2000) **131**, 1379–1384

Keywords: Nociceptin/orphanin FQ; nociceptin receptor antagonist; spatial learning; hippocampus

Abbreviations: Ca²⁺, calcium ion; CHO, Chinese hamster ovary; KO, knockout; NaCl, sodium chloride; OP, opioid; ORL, opioid receptor-like

Introduction

A G-protein-coupled receptor, previously known as ORL 1 (Opioid Receptor-Like 1) now known as OP₄/nociceptin (Hamon, 1998; Calo *et al.*, 2000a,b), which is sequentially homologous with opioid (OP) receptors but not activated by known opioid ligands, has recently been identified and cloned (Bunzow *et al.*, 1994; Chen *et al.*, 1994; Mollereau *et al.*, 1994). An endogenous agonist for OP₄/nociceptin receptors was later identified (Meunier *et al.*, 1995; Reinscheid *et al.*, 1995) and named orphanin FQ or nociceptin.

Nociceptin is a 17-amino acid peptide structurally related to opioid peptides, in particular, to dynorphin A. However, nociceptin is devoid of any activity at OP₁, OP₂ or OP₃ opioid receptor subtypes (Meunier *et al.*, 1995; Reinscheid *et al.*, 1995). Since its discovery, a surge of scientific investigation has implicated a role for nociceptin in pain, fear and anxiety, feeding circadian rhythms (see Harrison & Grandy, 2000; Calo *et al.*, 2000b for recent reviews).

Moreover, *in situ* hybridization and immunohistochemical studies, in rodents, have demonstrated that both OP₄/nociceptin mRNA and receptor protein are found in high concentrations in the hippocampus, brainstem and cortex, areas of the brain involved in higher functions including learning and memory processing (Henderson & McKnight, 1997; Meunier, 1997; Darland *et al.*, 1998).

Several behavioural studies have suggested a role for nociceptin in learning and memory using different animal models. For example, the hippocampal administration of nociceptin impaired learning of a spatial memory task in rats (Sandin *et al.*, 1997) and mice (Hiramatsu & Inoue, 1999), whereas nociceptin receptor knockout mice presented enhanced performance in spatial learning/attention tasks (Mamiya *et al.*, 1998; Manabe *et al.*, 1998; Nabeshima *et al.*, 1999).

Recent studies concerning the possible role played by nociceptin in learning and memory have mainly concentrated on gene knockout (KO) experiments, as specific nociceptin receptor antagonists have not been available. While KO approaches are certainly most useful at present, it is difficult to exclude compensatory developmental effects of gene deletion. Recently one antagonist, [Nphe¹]-Nociceptin (1-13)-NH₂, which is devoid of any residual agonist activity has been developed (Calo *et al.*, 2000a). This novel molecule selectively antagonized the effects of nociceptin *in vitro* in various isolated tissues and in CHO cells expressing the human recombinant nociceptin receptor (Rizzi *et al.*, 1999; Calo *et al.*, 2000b; Hashimoto *et al.*, 2000). [Nphe¹]-Nociceptin (1-13)-NH₂ is also active *in vivo* to prevent the pro-nociceptive and anti-morphine actions of nociceptin in the mouse tail withdrawal assay and the hyperphagic effect of nociceptin in the rat (Calo *et al.*, 1998; Polidori *et al.*, 2000).

It was therefore of significant interest to investigate the effects of this new antagonist on purported nociceptin-induced deficits in spatial learning in the Morris water maze

*Author for correspondence; E-mail: mcou@musica.mcgill.ca

task, a behavioural model in which the ability of a rat to locate a hidden platform is dependent on the integrative functioning of the hippocampal formation (Morris *et al.*, 1982). In addition, experiments were performed to investigate any peptide-induced changes in exploratory behaviour that may have interfered with the interpretation of Morris water maze data.

Methods

Subjects

Forty-eight young adult male Sprague Dawley rats (Charles River, St-Constant, Quebec, Canada), weighing 350–400 g, were housed under standard laboratory conditions (12 h light/12 h dark cycle, lights on at 0700 h, food and water *ad libitum*). Animal care was provided according to protocols and guidelines approved by McGill University and the Canadian Council of Animal Care.

Surgery

Prior to administration of anaesthetic, animals received an intraperitoneal injection (IP) of sterile atropine sulphate (0.04 mg kg^{-1}) to minimize respiratory difficulties that may have been invoked by the anaesthetic. Following a delay of 15 min, animals were carefully weighed and administered sodium pentobarbital (50 mg kg^{-1} , IP). The respiratory rate was monitored throughout the entire surgical procedure. Animals were then implanted bilaterally with permanent 26 gauge steel guide cannula (Plastics One, Roanoke, VA, U.S.A.) in the CA3 region of the dorsal hippocampus. Coordinates were taken from the atlas of Paxinos & Watson (1986): anterior-posterior, -3.3 mm with respect to bregma; lateral, $\pm 2.7 \text{ mm}$ with respect to the midsagittal suture line; ventral, -4.3 mm (injection site) with respect to the surface of the skull. The animals were then placed under a warming lamp until they had sufficiently recovered from the anaesthetic, before being individually housed for a period of 7 days post-surgery.

Treatment

The rats were randomly divided into four groups ($n=12$) and treated with: (1) isotonic NaCl $\rightarrow$ 5 nmole nociceptin (control/nociceptin group); (2) 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ $\rightarrow$ isotonic NaCl (antagonist/control group); (3) 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ $\rightarrow$ 5 nmole nociceptin (antagonist/nociceptin group) or (4) isotonic NaCl $\rightarrow$ isotonic NaCl (control/control group), injected bilaterally (total injection volume: $1 \mu\text{l}$; flow-rate: $0.5 \mu\text{l min}^{-1}$) with a microinfusion pump (Carnegie Medicine, Stockholm, Sweden). Pretreatment was performed 5 min before the second injection, and testing began 15 min after the second intrahippocampal injection. Doses (considered intermediate) were chosen on the basis of previously reported *in vivo* studies, together with binding data of nociceptin and [Nphe¹]-Nociceptin (1-13)-NH₂ in transfected CHO cells expressing recombinant human OP₄ receptors (Calo' *et al.*, 2000a,b; Sandin *et al.*, 1997).

Spatial learning

A circular pool, 160 cm in diameter, was used for Morris water maze experiments (Quirion *et al.*, 1995). The pool was

filled up with tap water, made opaque with powdered milk, and maintained at $22 \pm 1^\circ\text{C}$. The escape platform (diameter 15 cm) was placed in the pool so that it was submerged 2 cm below the water surface. All animals were given four trials per day over three consecutive days. For each trial, the rat was placed in the pool (facing pool wall) at one of four selected starting points (North, South, East or West pole). On locating the platform, the rat was allowed to remain there for 30 s before being returned to its cage. If the rat did not find the platform within 120 s, it was guided to the platform by hand and allowed to remain there for 30 s. An inter-trial period of 5 min was employed. The escape latency and swim speed were measured by a video tracking system connected to a computer equipped with the commercially available HVS image system (HVS, U.K.) for the analysis of Morris water maze performance. On the morning after the last training trial, animals were subjected to a probe trial in which the platform was removed. Animals were placed in the pool at the same pole and allowed to swim for 2 min. The time that each animal spent in the quadrant that had previously contained the hidden platform was measured. This trial is necessary to confirm that the spatial navigation task was learned using environmental cues. Afterwards, animals were subjected to another trial in which the platform was made visible, thus eliminating any misinterpretation of results due to drug-induced impairment of vision.

Exploratory behaviour

Seven days after the last trial, rats received isotonic NaCl, nociceptin or [Nphe¹]-Nociceptin (1-13)-NH₂ as described above, 15 min before examination of exploratory behaviour in an 'open field' (Gray & Lalljee, 1974). Each animal was placed into the centre of the apparatus, which consisted of a square base ($90 \times 90 \text{ cm}$) divided into 10 cm squares by faint black lines. The wall surrounding the base consisted of a 75 cm high wall covered with aluminium foil. Illumination was provided by a 60 W bulb, positioned 90 cm above the floor of the apparatus. The number of squares crossed, rearing, grooming and faecal boli deposited were measured over a 3 min test period by an investigator unaware of the treatment regime. Such a testing period has been shown to be sufficient to detect changes in exploratory behaviour in a novel environment. Immediately after the experiments, all rats were decapitated and the brain was removed and sliced to visually confirm the position of the cannulae in fresh tissue. No subjects were excluded from the data analysis because of improper cannula placement, and tissue damage was minimal.

Statistics

Statistical analyses were performed using a two-way analysis of variance where treatment and trial were first and second factors, followed by *post hoc* Bonferroni tests to assess individual group differences. Data were considered statistically significant when $P < 0.05$.

Results

As shown in Figure 1A, bilateral intrahippocampal injection of 5 nmole nociceptin significantly impaired the rat's ability to locate the hidden platform throughout the 3 days training, compared with control performance ($F_{1,66} = 177.5$, $P < 0.001$). Fifty nmole [Nphe¹]-Nociceptin (1-13)-NH₂ did not display

Figure 1 Effect of intrahippocampal injection of nociceptin and [Nphe¹]-Nociceptin (1-13)-NH₂ on escape latency in the Morris water maze task (hidden platform). Animals were microinjected with isotonic NaCl, 5 nmole nociceptin, 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ or [Nphe¹]-Nociceptin (1-13)-NH₂/nociceptin. (A) Data are expressed as mean latency $\pm$ s.e.mean (averaged over four trials per session; $n = 12$). (B) Data are expressed as mean latency $\pm$ s.e.mean of each trial (12 trials during training; $n = 12$). ** $P < 0.01$, *** $P < 0.001$ versus NaCl; + $P < 0.05$, ++ $P < 0.01$, +++ $P < 0.001$ versus nociceptin.

any effect *per se* but significantly antagonized nociceptin-induced impairment of spatial learning ($F_{1,66} = 64.13$, $P < 0.001$). It is noteworthy that nociceptin-treated animals failed to show any trial-to-trial improvement in spatial learning, whereas animals that were pretreated with [Nphe¹]-Nociceptin (1-13)-NH₂ presented learning patterns that were not significantly different from control animals. Escape latencies of animals that were treated with [Nphe¹]-Nociceptin (1-13)-NH₂ alone were similar to that of the isotonic NaCl-treated control group (Figure 1B).

Results from the probe trial indicated that vehicle-treated control animals had learned the spatial navigation task using environmental cues as they spent more time in the quadrant (goal area) that had contained the hidden platform during training (Figure 2). In contrast, nociceptin-treated animals did not spend more time in any one specific quadrant. Animals treated in combination with nociceptin/[Nphe¹]-Nociceptin (1-13)-NH₂, or [Nphe¹]-Nociceptin (1-13)-NH₂ alone, displayed similar activity to vehicle-treated control animals, i.e., they spent more time in the goal area of the pool.

Analysis of swim speed indicated that there were no significant differences in swimming ability between control group and drug-treated groups (Figure 3). When animals were presented with a visible platform, there were no significant differences in the time taken to locate the platform between vehicle-control and drug-treated animals (Figure 4).

The results from the 'open field' test are shown in Figure 5. Analysis of the data revealed no significant differences in ambulation, exploratory rearing, grooming or faecal boli deposited between the different groups.

Figure 2 Effect of intrahippocampal injection of nociceptin and [Nphe¹]-Nociceptin (1-13)-NH₂ on escape latency in the Morris water maze task (probe trial). Animals were microinjected with isotonic NaCl, 5 nmole nociceptin, 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ or [Nphe¹]-Nociceptin (1-13)-NH₂/nociceptin. Data are expressed as mean latency $\pm$ s.e.mean ($n = 12$). ** $P < 0.01$ versus NaCl.

Figure 3 Effect of intrahippocampal injection of nociceptin and [Nphe¹]-Nociceptin (1-13)-NH₂ on swim speed in the Morris water maze task (hidden platform). Animals were microinjected with isotonic NaCl, 5 nmole nociceptin, 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ or [Nphe¹]-Nociceptin (1-13)-NH₂/nociceptin. Data are expressed as cumulative mean latency $\pm$ s.e.mean (averaged over 12 trial training sessions; $n = 12$).

Discussion

The present study demonstrates that bilateral injection of nociceptin into the CA3 region of the hippocampus induced a significant impairment in the learning of a spatial memory task, the Morris water maze, which is dependent on the integrative functioning of the hippocampal formation (Morris *et al.*, 1982). Such impairments were not attributable to non-specific deficits in motor performance or change in exploratory behaviour. Most importantly, pretreatment with [Nphe¹]-Nociceptin (1-13)-NH₂, a nociceptin receptor antagonist, prevented nociceptin-induced deficits. To our knowledge this is the first evidence using a pure pharmacological approach, i.e. nociceptin receptor blockade, that indicates a role for the nociceptin and its receptor in learning and memory. Other studies have used a molecular strategy, i.e.,

Figure 4 Effect of intrahippocampal injection of nociceptin on escape latency in the Morris water maze task (visible platform). Animals were microinjected with isotonic NaCl, 5 nmole nociceptin, 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ or [Nphe¹]-Nociceptin (1-13)-NH₂/nociceptin. Data are expressed as mean latency $\pm$ s.e.mean ($n = 12$).

Figure 5 Effect of intrahippocampal injection of nociceptin and [Nphe¹]-Nociceptin (1-13)-NH₂ on exploratory behaviour. Animals were microinjected with isotonic NaCl, 5 nmole nociceptin, 50 nmole [Nphe¹]-Nociceptin (1-13)-NH₂ or [Nphe¹]-Nociceptin (1-13)-NH₂/nociceptin. Data are expressed as mean $\pm$ s.e.mean ($n = 12$).

gene knockout. The present approach rules out the possibility of developmental interference following gene deletion. Our data support a role for nociceptin and its receptor in cognitive processes.

Behavioural studies, in which the influence of OP₄/nociceptin receptors is removed by gene knockout, have suggested that nociceptin may have some tonic control over learning and memory processing (Mamiya *et al.*, 1998; Manabe *et al.*, 1998; Hiramatsu & Inoue, 1999; Nabeshima *et al.*, 1999). In the present experiments, intrahippocampal administration of [Nphe¹]-Nociceptin (1-13)-NH₂ alone failed to enhance learning of the task when compared to control performance. Hence additional events (occurring during embryogenesis and development) invoking compensatory adaptation following gene deletion, could explain the apparent tonic effect of nociceptin on learning observed in previous studies.

The results of the present study cannot be explained on the basis of motor impairments in the Morris water maze apparatus, as analysis of swim speed did not reveal any differences in swimming ability between control or drug-treated groups. In addition, possible nociceptin-induced impairment of visual capacity was ruled out by the results obtained when the escape platform was made visible. Nociceptin-treated animals located the platform with an escape latency comparable to that of NaCl-treated control animals. Hence, nociceptin-induced impairment of learning is a specific cognitive effect and is truly mediated by nociceptin receptors as these effects are antagonized by [Nphe¹]-Nociceptin (1-13)-NH₂.

Testing in the 'open field', revealed that drug treatment did not significantly affect ambulation in a novel environment or exploratory rearing. Previous studies have suggested a role for nociceptin in the mediation of exploratory locomotor behaviour. Such changes in locomotor activity were detected in the first 5 min of testing, and support the use of a 3 min testing period in the present study. However, this subject remains controversial with both decreases (Reinscheid *et al.*, 1995; Devine *et al.*, 1996; Sandin *et al.*, 1997) and increases (Florin *et al.*, 1996) in locomotion being reported. A possible explanation is related to doses, with lower doses of nociceptin inducing increased locomotor activity while higher doses decreased exploratory locomotor behaviour. The dose of nociceptin used in the present study would be considered intermediate compared to those previously reported in *in vivo* studies (Calo' *et al.*, 2000b). A further explanation may be that the animals became tolerant to nociceptin-induced changes in locomotion. Indeed, it has been demonstrated that rats rapidly developed tolerance to the locomotor-inhibiting effects of nociceptin, and this tolerance was still apparent 7 days after the final injection (Devine *et al.*, 1996). In addition, previous studies have used intracerebroventricular injections of nociceptin, after which the peptide may be rather freely distributed possibly acting on brain regions involved in motor behaviours. In contrast, the results of the present study were obtained after discrete injections of nociceptin into the CA3 region of the hippocampus, and suggest that this region may not play an important role in the mediation of exploratory locomotor activity induced by nociceptin and its receptors. However, firm conclusions are difficult to substantiate as the present study used only one dose of each peptide.

Recent studies have suggested possible cellular mechanisms involved in nociceptin-induced amnesia. It has been shown that nociceptin inhibited the release of glutamate from cerebral cortical slices (Nicol *et al.*, 1996) and inhibited Ca²⁺ currents in hippocampal pyramidal cells (Knoflach *et al.*, 1996). In addition, electrophysiological studies have demonstrated that OP₄/nociceptin receptors can couple to inwardly rectifying K⁺ channels in hippocampal preparations, and that nociceptin induces the activation of such channels (Ikeda *et al.*, 1997). Furthermore, nociceptin inhibited synaptic transmission and synaptic plasticity such as long-term potentiation (LTP) in the rat hippocampus and dentate gyrus (Yu *et al.*, 1997; Yu & Xie, 1998). [Nphe¹]-Nociceptin (1-13)-NH₂, by blocking nociceptin receptors, may prevent such agonist-induced effects and hence antagonize nociceptin-induced impairments of learning and memory.

The pharmacokinetics of nociceptin have not yet been studied in detail. Few experiments have been performed investigating the metabolism of the peptide *in vitro* in human blood (Yu *et al.*, 1996), in cell culture (Vlaskovska *et al.*, 1999), and in mouse brain cortical slices (Montiel *et al.*, 1997). *In vivo* experiments in the rat hippocampus (Sandin *et al.*, 1997) and in the mouse brain after intracerebroventricular administration (Noble & Roques, 1997) have also been performed. In the latter study, it was demonstrated that the association of different peptidase inhibitors potentiated the behavioural effects of nociceptin on motor behaviour, suggesting that as for other neuropeptides, interruption of the responses induced by nociceptin is ensured by enzymes which cleave the peptide into inactive fragments. To our knowledge, there are no data related to the pharmacokinetics of [Nphe¹]-Nociceptin (1-13)-NH₂. The few experiments performed *in vivo* with this molecule indicated that its

duration of action is similar to that of nociceptin, around 30 min (See Calo *et al.*, 2000b for review).

In summary, the results from the present study support and extend those of Sandin *et al.* (1997) in that bilateral intrahippocampal (CA3 region) injection of nociceptin provoked marked impairments in spatial learning in the Morris water maze task, results which are consistent with the dense localization of OP₄/nociceptin receptors in the hippocampal formation (Mollereau *et al.*, 1994). Most interestingly, this study demonstrates that such learning impairments are truly mediated by OP₄/nociceptin receptors,

as pretreatment with the recently developed nociceptin receptor antagonist, [Nphe¹]-Nociceptin (1-13)-NH₂, reversed nociceptin-induced deficits in escape latency. By itself, this antagonist was devoid of any activity. Taken together, this study supports the idea that [Nphe¹]-Nociceptin (1-13)-NH₂ represents an effective *in vivo* antagonist at the nociceptin receptors involved in learning and memory.

This study was supported by a Medical Research Council of Canada grant to R. Quirion.

References

- BUNZOW, J.R., SAEZ, C., MORTRUD, M., BOUVIER, C., WILLIAMS, J.T., LOW, M. & GRANDY, D.K. (1994). Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not mu, delta or kappa opioid receptor type. *FEBS Lett.*, **347**, 284–288.
- CALO', G., GUERRINI, R., BIGONI, R., RIZZI, A., MARZOLA, G., OKAWA, H., BIANCHI, C., LAMBERT, D.G., SALVADORI, S. & REGOLI, D. (2000a). Characterization of [Nphe¹]-Nociceptin (1-13)-NH₂, a new selective nociceptin antagonist. *Br. J. Pharmacol.*, **129**, 1183–1193.
- CALO', G., GUERRINI, R., RIZZI, A., SALVADORI, S. & REGOLI, D. (2000b). Pharmacology of nociceptin and its receptor: a novel therapeutic target. *Br. J. Pharmacol.*, **129**, 1261–1283.
- CALO', G., RIZZI, A., MARZOLA, G., GUERRINI, R., SALVADORI, S., BEANI, L., REGOLI, D. & BIANCHI, C. (1998). Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. *Br. J. Pharmacol.*, **125**, 373–378.
- CHEN, Y., FAN, Y., LIU, J., MESTEK, A., TIAN, M., KOZAK, C.A. & YU, L. (1994). Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. *FEBS Lett.*, **347**, 279–283.
- DARLAND, T., HEINRICHER, M.M. & GRANDY, D.K. (1998). Orphanin FQ/nociceptin: a role in pain and analgesia, but so much more. *Trends Neurosci.*, **21**, 215–221.
- DEVINE, D.P., TAYLOR, L., REINSCHIED, R.K., MONSMA, F.J., CIVELLI, O. & AKIL, H. (1996). Rats rapidly develop tolerance to locomotor-inhibiting effects of the novel neuropeptide orphanin FQ. *Neurochem. Res.*, **21**, 1387–1396.
- FLORIN, S., SUAUDEAU, C., MEUNIER, J.C. & COSTENTIN, J. (1996). Nociceptin stimulates locomotion and exploratory behavior in mice. *Eur. J. Pharmacol.*, **317**, 9–13.
- GRAY, J.A. & LALLJEE, B. (1974). Sex differences in emotional behaviour in the rat: correlation between 'open field' defaecation and active avoidance. *Anim. Behav.*, **22**, 856–861.
- HAMON, M. (1998). The new approach to opioid receptors. *N.S. Arch. Pharmacol.*, **358**, SA 5.3.
- HARRISON, L.M. & GRANDY, D.K. (2000). Opiate modulating properties of nociceptin/orphanin FQ. *Peptides*, **21**, 151–172.
- HASHIMOTO, Y., CALO', G., GUERRINI, R., SMITH, G. & LAMBERT, D.G. (2000). Antagonistic effects of [Nphe¹]-Nociceptin (1-13)-NH₂ on nociceptin mediated inhibition of cAMP formation in Chinese ovary cells stably expressing the recombinant human nociceptin receptor. *Neurosci. Lett.*, **278**, 109–112.
- HENDERSON, G. & MCKNIGHT, A.T. (1997). The orphan opioid receptor and its endogenous ligand—nociceptin/orphanin FQ. *Trends Pharmacol. Sci.*, **18**, 293–300.
- HIRAMATSU, M. & INOUE, K. (1999). Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice. *Eur. J. Pharmacol.*, **367**, 151–155.
- IKEDA, K., KOBAYASHI, K., KOBAYASHI, T., ICHIKAWA, T., KUMANISHI, T., KISHIDA, H., YANO, R. & MANABE, T. (1997). Functional coupling of the nociceptin/orphanin FQ receptor with the G-protein-activated K⁺ (GIRK) channel. *Mol. Brain Res.*, **45**, 117–126.
- KNOFLACH, F., REINSCHIED, R.K., CIVELLI, O. & KEMP, J.A. (1996). Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. *J. Neurosci.*, **16**, 6657–6664.
- MAMIYA, T., NODA, Y., NISHI, M., TAKESHIMA, H. & NABESHIMA, T. (1998). Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. *Brain Res.*, **783**, 236–240.
- MANABE, T., NODA, Y., MAMIYA, T., KATAGIRI, H., HOUTANI, T., NISHI, M., NODA, T., TAKAHASHI, T., SUGIMOTO, T., NABESHIMA, T. & TAKESHIMA, H. (1998). Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. *Nature*, **394**, 577–581.
- MEUNIER, J.C. (1997). Nociceptin/orphanin FQ and the opioid receptor-like ORL 1 receptor. *Eur. J. Pharmacol.*, **340**, 1–15.
- MEUNIER, J.C., MOLLEREAU, C., TOLL, L., SUAUDEAU, C., MOISAND, C., ALVINERIE, P., BUTOUR, J.L., GUILLEMOT, J.C., FERRARA, P., MONSERRAT, B., MAZARGUIL, H., VASSART, G., PARMENTIER, M. & COSTENTIN, J. (1995). Isolation and structure of the endogenous agonist of opioid receptor-like ORL 1 receptor. *Nature*, **377**, 532–535.
- MOLLEREAU, C., PARMENTIER, M., MAILLEUX, P., BUTOUR, J.L., MOISAND, C., CHALON, P., CAPUT, D., VASSART, G. & MEUNIER, J.C. (1994). ORL 1, a novel member of the opioid receptor family. Cloning, functional expression and localization. *FEBS Lett.*, **341**, 33–38.
- MONTIEL, J.L., CORNILLE, F., ROQUES, B.P. & NOBLE, F. (1997). Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. *J. Neurochem.*, **68**, 354–361.
- MORRIS, R.G.M., GARRUD, P., RAWLINS, J.N.P. & O'KEEFE, J. (1982). Place navigation impaired in rats with hippocampal lesions. *Nature*, **297**, 681–683.
- NABESHIMA, T., NODA, Y. & MAMIYA, T. (1999). The role of nociceptin in cognition. *Brain Res.*, **848**, 167–173.
- NICOL, B., LAMBERT, D.G., ROWBOTHAM, D.J., SMART, D. & MCKNIGHT, A.T. (1996). Nociceptin induced inhibition of K⁺ evoked glutamate release from rat cerebrocortical slices. *Br. J. Pharmacol.*, **119**, 1081–1083.
- NOBLE, F. & ROQUES, B.P. (1997). Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioural effects mediated by nociceptin/orphanin FQ in mice. *FEBS Lett.*, **401**, 227–229.
- PAXINOS, G. & WATSON, C. (1986). *The rat brain in stereotaxic coordinates*. Orlando FL: Academic Press.
- POLIDORI, C., CALO', G., CICCOCIOPPO, R., GUERRINI, R., REGOLI, D. & MASSI, M. (2000). Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist. *Psychopharmacology*, **148**, 430–437.
- QUIRION, R., WILSON, A., ROWE, W., AUBERT, I., RICHARD, J., DOODS, H., PARENT, A., WHITE, N. & MEANEY, M.J. (1995). Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. *J. Neurosci.*, **15**, 1455–1462.
- REINSCHIED, R.K., NOTHACKER, H.P., BOURSON, A., ARDATI, A., HENNINGSSEN, R.A., BUNZOW, J.R., GRANDY, D.K., LANGEN, H., MONSMA, F.J. Jr. & CIVELLI, O. (1995). Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor. *Science*, **270**, 792–794.
- RIZZI, A., BIGONI, R., CALO', G., GUERRINI, R., SALVADORI, S. & REGOLI, D. (1999). [Nphe¹]-Nociceptin (1-13)-NH₂ antagonizes nociceptin effects in the mouse colon. *Eur. J. Pharmacol.*, **385**, R3–R5.
- SANDIN, J., GEORGIEVA, J., SCHÖTT, P.A., ÖGREN, S.O. & TERENIUS, L. (1997). Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. *Eur. J. Neurosci.*, **9**, 149–197.

- VLASKOVSKA, M., KASAKOV, L., SUDER, P., SILBERRING, J. & TERENIUS, L. (1999). Biotransformation of nociceptin/orphanin FQ by enzyme activity from morphine-naïve and morphine treated cell cultures. *Brain Res.*, **818**, 212–220.
- YU, T.P. & XIE, C.W. (1998). Orphanin FQ/nociceptin inhibits synaptic transmission and long-term potentiation in rat dentate gyrus through postsynaptic mechanisms. *J. Neurophysiol.*, **80**, 1277–1284.
- YU, T.P., CHAIT, B.T., TOLL, L. & KREEK, M.J. (1996). Nociceptin in vitro biotransformation in human blood. *Peptides*, **17**, 873–876.
- YU, T.P., FEIN, J., PHAN, T., EVANS, C.J. & XIE, C.W. (1997). Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. *Hippocampus*, **7**, 88–94.

(Received June 22, 2000

Revised August 10, 2000

Accepted September 18, 2000)